A hormone therapy trial after prostate surgery to prevent return
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests whether adding apalutamide to standard hormone therapy (ADT) after prostate surgery can lower the chance that prostate cancer comes back. It targets men at higher risk of recurrence based on PSA levels and a risk score from surgical findings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 18 to 75 with prostate cancer confirmed by tissue testing
- Your prostate cancer surgery was within the last 12 weeks, and your PSA blood test is below 0.1 within 8 weeks after surgery
- Your risk score after surgery (CAPRA-S) is 6 or higher, meaning higher risk of recurrence
- You can get to study visits and do daily activities fairly normally (ECOG performance status 0 to 1)
- Blood counts and organ tests (kidney, liver, clotting) are in safe ranges to start treatment
- You have not had certain prior treatments like ADT, chemotherapy, radiation, or prostate antiandrogen drugs before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
This trial compares two ways of giving hormone therapy (apalutamide) along with radiation after prostate removal surgery. It aims to see which approach helps maintain quality of life while controlling cancer.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.